US5780587A
(en)
*
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
US5877015A
(en)
*
|
1991-01-21 |
1999-03-02 |
Imperial College Of Science, Technology Of Medicine |
APP770 mutant in alzheimer's disease
|
WO1993014200A1
(en)
*
|
1992-01-07 |
1993-07-22 |
Tsi Corporation |
Transgenic animal models for alzheimer's disease
|
US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
DK0730643T3
(da)
*
|
1993-10-27 |
2001-05-14 |
Elan Pharm Inc |
Transgene dyr, som huser APP-allel med svensk mutation
|
US5877399A
(en)
*
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
EP0742831B1
(de)
|
1994-01-27 |
2004-09-29 |
The Regents Of The University Of Minnesota |
Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
|
US7427392B1
(en)
*
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
CA2221986A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
US6717031B2
(en)
*
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6043283A
(en)
*
|
1996-09-20 |
2000-03-28 |
Baylor College Of Medicine |
Tyramine compounds and their neuronal effects
|
US6071493A
(en)
|
1996-09-20 |
2000-06-06 |
Baylor College Of Medicine |
Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US8173127B2
(en)
*
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US6455757B1
(en)
|
1997-10-08 |
2002-09-24 |
The Regents Of The University Of California |
Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
|
US6175057B1
(en)
|
1997-10-08 |
2001-01-16 |
The Regents Of The University Of California |
Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
AU781126B2
(en)
*
|
1997-12-03 |
2005-05-05 |
Janssen Alzheimer Immunotherapy |
Method of suppressing beta-amyloid-related changes in Alzheimer's disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
ATE323757T1
(de)
*
|
1998-05-15 |
2006-05-15 |
Ortho Mcneil Pharm Inc |
Im irak-gen modifizierte transgene mäuse
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6313268B1
(en)
|
1998-10-16 |
2001-11-06 |
Vivian Y. H. Hook |
Secretases related to Alzheimer's dementia
|
US6245884B1
(en)
|
1998-10-16 |
2001-06-12 |
Vivian Y. H. Hook |
Secretases related to alzheimer's dementia
|
US6737038B1
(en)
*
|
1998-11-12 |
2004-05-18 |
Bristol-Myers Squibb Company |
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
|
WO2000037483A1
(en)
*
|
1998-12-22 |
2000-06-29 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative disorders
|
US7115410B1
(en)
*
|
1999-02-10 |
2006-10-03 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
AU4078900A
(en)
|
1999-04-06 |
2000-10-23 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
US20030131364A1
(en)
*
|
1999-04-27 |
2003-07-10 |
Karen Duff |
Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
|
US6670195B1
(en)
|
1999-05-26 |
2003-12-30 |
New York University |
Mutant genes in Familial British Dementia and Familial Danish Dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US7119085B2
(en)
*
|
2000-03-23 |
2006-10-10 |
Elan Pharmaceuticals, Inc. |
Methods to treat alzheimer's disease
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
WO2001073001A2
(en)
*
|
2000-03-24 |
2001-10-04 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Establishment of cellular manipulations which enhance oligo-mediated gene targeting
|
US7371920B2
(en)
*
|
2000-06-20 |
2008-05-13 |
The Governing Council Of The University Of Toronto |
Transgenic mouse model of neurodegenerative disorders
|
EP1666452A2
(de)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Verbindungen zur Behandlung der Alzheimerischen Krankheit
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
CA2410680A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Elan Pharmaceuticals, Inc. |
Compounds to treat alzheimer's disease
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
CA2414772C
(en)
*
|
2000-07-07 |
2011-06-28 |
Jan Naslund |
Prevention and treatment of alzheimer's disease
|
AU2007200047B2
(en)
*
|
2000-07-07 |
2009-11-26 |
Bioarctic Neuroscience Ab |
Prevention and treatment of Alzheimer's disease
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
CA2438832A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Elan Pharmaceuticals, Inc. |
Transgenic knockouts of bace-1
|
US6649196B2
(en)
*
|
2001-03-12 |
2003-11-18 |
Mayo Foundation For Medical Education And Research |
Methods of reducing β-amyloid polypeptides
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
DE60229051D1
(de)
*
|
2001-04-30 |
2008-11-06 |
Lilly Co Eli |
Humanisierte antikörper
|
CA2448834A1
(en)
*
|
2001-06-01 |
2002-12-12 |
Elan Pharmaceuticals, Inc. |
Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
|
AU2002315131A1
(en)
|
2001-06-13 |
2002-12-23 |
Elan Pharmaceuticals, Inc. |
Aminediols as agents for the treatment of alzheimer's disease
|
EP1532244A4
(de)
|
2001-06-14 |
2005-12-14 |
Bristol Myers Squibb Co |
Neue humane histon-deacetylasen
|
JP2005500319A
(ja)
*
|
2001-06-27 |
2005-01-06 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
|
AU2002312566A1
(en)
*
|
2001-07-09 |
2003-01-29 |
Elan Pharmaceuticals, Inc. |
Methods of inhibiting amyloid toxicity
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
JP2005505517A
(ja)
*
|
2001-07-10 |
2005-02-24 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病を治療するためのアミンジオール
|
JP2005504022A
(ja)
*
|
2001-07-10 |
2005-02-10 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病治療のためのジアミンジオール
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
EP1432674A2
(de)
*
|
2001-10-04 |
2004-06-30 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamine
|
AP2004003049A0
(en)
*
|
2001-11-08 |
2004-06-30 |
Elan Pharm Inc |
N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
|
AU2002352811A1
(en)
*
|
2001-11-19 |
2003-06-10 |
Elan Pharmaceuticals, Inc. |
Amino diols useful in the treatment of alzheimer's disease
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AU2003303141A1
(en)
*
|
2002-04-30 |
2004-07-22 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer's disease
|
US20040009602A1
(en)
*
|
2002-05-13 |
2004-01-15 |
The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services |
DNA modifying molecules and methods of use thereof
|
UY27967A1
(es)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
Acetil 2-hindroxi-1,3-diaminoalcanos
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
JP2006519762A
(ja)
*
|
2002-10-09 |
2006-08-31 |
ライナット ニューロサイエンス コーポレイション |
アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
US20080014194A1
(en)
*
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CA2504870A1
(en)
*
|
2002-11-04 |
2004-05-21 |
Bioarctic Neuroscience Ab |
Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
|
WO2004042074A2
(en)
*
|
2002-11-04 |
2004-05-21 |
Icogenex Corporation |
Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
|
PE20040762A1
(es)
|
2002-11-27 |
2004-11-06 |
Elan Pharm Inc |
Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
|
AU2003303198A1
(en)
|
2002-12-19 |
2004-07-14 |
New York University |
Method for treating amyloid disease
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
|
PE20050420A1
(es)
*
|
2003-04-21 |
2005-06-13 |
Elan Pharm Inc |
Fenacilo 2-hidroxi-3-diaminoalcanos
|
JP2006524255A
(ja)
*
|
2003-04-21 |
2006-10-26 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
ベンズアミド2−ヒドロキシ−3−ジアミノアルカン
|
WO2004110350A2
(en)
*
|
2003-05-14 |
2004-12-23 |
Torreypines Therapeutics, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
HUE035044T2
(en)
|
2003-05-19 |
2018-05-02 |
Prothena Biosciences Ltd |
Truncated fragments of alpha-synuclein in Lewy-body disease
|
US7358331B2
(en)
*
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
AT413336B
(de)
*
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
Apherese-vorrichtung
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
WO2005070407A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
JP2007528400A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
JP2007528403A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
JP2007528404A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換された尿素およびカルバメート、フェナシル−2−ヒドロキシ−3−ジアミノアルカン、ならびにベンズアミド−2−ヒドロキシ−3−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
|
JP2007528402A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
JP2007538024A
(ja)
*
|
2004-05-19 |
2007-12-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
|
CA2568201C
(en)
|
2004-05-24 |
2013-07-30 |
Universitat Zu Koln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
SE0401601D0
(sv)
|
2004-06-21 |
2004-06-21 |
Bioarctic Neuroscience Ab |
Protofibril specific antibodies and uses thereof
|
WO2006010095A2
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
AU2005265354A1
(en)
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
EA016357B1
(ru)
*
|
2004-07-30 |
2012-04-30 |
Ринат Ньюросайенс Корп. |
Антитела, направленные против бета-амилоидного пептида, и способы их применения
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
EP1802574A2
(de)
*
|
2004-08-27 |
2007-07-04 |
Elan Pharmaceuticals Inc. |
Verfahren zur behandlung von amyloidose mit ethanolcyclicaminderivat-aspartylproteasehemmern
|
TW200636066A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
WO2006066089A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
AR051800A1
(es)
*
|
2004-12-15 |
2007-02-07 |
Wyeth Corp |
Anticuerpos a beta usados en mejorar la cognicion
|
EP1859277A4
(de)
|
2005-02-17 |
2010-03-17 |
Biogen Idec Inc |
Behandlung neurologischer störungen
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
EP1746092A1
(de)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
|
US20080293680A1
(en)
*
|
2005-08-03 |
2008-11-27 |
Stefan Peters |
Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
|
CA2618019A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Compounds for the treatment of alzheimer's disease
|
CA2618013A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Beta-secretase inhibitors for use in the treatment of alzheimer's disease
|
JP2009504614A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルツハイマー病の治療用化合物
|
JP2009504613A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルツハイマー病の治療用化合物
|
WO2007047306A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
PT1976877E
(pt)
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
EP1954718B1
(de)
|
2005-11-30 |
2014-09-03 |
AbbVie Inc. |
Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
|
ES2316209B1
(es)
*
|
2005-12-02 |
2009-11-13 |
Universidad Autonoma De Madrid |
Modelo animal de enfermedad de alzheimer, procedimiento de obtencion y sus aplicaciones.
|
US7776882B2
(en)
*
|
2006-02-06 |
2010-08-17 |
Baxter Ellen W |
2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
WO2007092854A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
|
WO2007092839A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
|
EP2325209A3
(de)
|
2006-03-23 |
2011-08-03 |
BioArtic Neuroscience AB |
Verbesserte protofibril selektive Antikörper und deren Verwendung
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
US20070292895A1
(en)
*
|
2006-05-19 |
2007-12-20 |
Xiao-Ping Shi |
Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
|
JP2009538924A
(ja)
|
2006-06-01 |
2009-11-12 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Appの神経活性断片
|
WO2008011348A2
(en)
|
2006-07-14 |
2008-01-24 |
Ac Immune S.A. |
Humanized antibody against amyloid beta
|
SG10201502642TA
(en)
|
2006-10-12 |
2015-05-28 |
Bhi Ltd Partnership |
Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP3067066B1
(de)
|
2007-02-23 |
2019-03-27 |
Prothena Biosciences Limited |
Verhinderung und behandlung synukleinopathischer und amyloidogener krankheiten
|
CA2678963C
(en)
*
|
2007-02-23 |
2018-05-01 |
Elan Pharmaceuticals, Inc. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8147833B2
(en)
*
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2134863B1
(de)
|
2007-03-13 |
2014-05-21 |
The Children's Hospital Of Philadelphia |
Genetische veränderungen auf chromosom 16 und verfahren zur verwendung davon bei der diagnose von typ-1-diabetes
|
KR20100016661A
(ko)
*
|
2007-04-18 |
2010-02-12 |
얀센 알츠하이머 이뮤노테라피 |
대뇌 아밀로이드 혈관병증의 예방 및 치료
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
JP5450407B2
(ja)
|
2007-07-06 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
|
US20090023158A1
(en)
*
|
2007-07-13 |
2009-01-22 |
Elan Pharmaceuticals, Inc. |
Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
|
EP2182983B1
(de)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
|
WO2009048539A2
(en)
|
2007-10-05 |
2009-04-16 |
Genentech, Inc. |
Monoclonal antibody
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
US20090163594A1
(en)
*
|
2007-10-31 |
2009-06-25 |
Elan Pharmaceuticals, Inc. |
Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
|
NZ586831A
(en)
*
|
2008-01-28 |
2012-02-24 |
Janssen Pharmaceutica Nv |
6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
|
NZ586830A
(en)
*
|
2008-01-29 |
2012-02-24 |
Janssen Pharmaceutica Nv |
2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
|
AU2009215441B2
(en)
|
2008-02-19 |
2015-07-02 |
The Children's Hospital Of Philadelphia |
Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
|
WO2009140679A2
(en)
|
2008-05-16 |
2009-11-19 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
EP2448968B1
(de)
|
2009-06-29 |
2021-01-27 |
BioArctic AB |
Selektive antikörper für n-terminal trunkierte amyloid-beta-protofibrillen/oligomere
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
RU2607368C2
(ru)
|
2010-07-30 |
2017-01-10 |
Ац Иммуне С.А. |
Безопасные и функциональные гуманизированные антитела
|
EP2603524A1
(de)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
MX353096B
(es)
|
2010-08-19 |
2017-12-19 |
Buck Institute For Age Res Star |
Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
|
JP6482458B2
(ja)
|
2012-03-19 |
2019-03-13 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
App特異性のbace(asbi)およびその使用
|
AU2014216390B2
(en)
|
2013-02-12 |
2018-05-10 |
Buck Institute For Research On Aging |
Hydantoins that modulate BACE-mediated APP processing
|
SI3166970T1
(sl)
|
2014-07-10 |
2021-09-30 |
Bioarctic Ab |
Izboljšana A-beta protofibril vezavna protitelesa
|
US10704098B2
(en)
|
2014-10-29 |
2020-07-07 |
The Children's Hospital Of Philadelphia |
Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
|
EP3730188A1
(de)
|
2015-08-21 |
2020-10-28 |
The Children's Hospital of Philadelphia |
Zusammensetzungen und verfahren zur verwendung in kombination zur behandlung und diagnose von autoimmunerkrankungen
|
JP2018525447A
(ja)
|
2015-08-27 |
2018-09-06 |
ナントネウロ,エルエルシー |
App選択的bace阻害のための組成物およびそのための使用
|
JP7027341B2
(ja)
|
2016-05-12 |
2022-03-01 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
Appの正常なプロセシングを促進する化合物
|